HDAC4 and Glomerular sclerosis: DTsiANp/HDAC4 is designed to delivery HDAC4 siRNA to the podocytes in DKD rat model, after four weeks treatment, the glucose level, urinary albumin excretion ratio (UAER), MCs proliferation and glomerular sclerosis are all reduced significantly (Raval et al., 2019).